Island Pharmaceuticals

island (asx: ila) is a mid clinical-stage research drug repurposing company, focused on the rapid development of antiviral therapeutics for infectious diseases. we have a lead asset – isla-101 - that was initially developed by our wholly-owned subsidiary, isla pharmaceuticals. isla-101 is a drug with a well-established safety profile, being repurposed for the prevention and treatment of dengue fever and other mosquitoes (or vector) borne diseases. dengue fever is the very definition of an unmet medical need. while 390 million humans are infected each year, it is thought that around 30-50% of people with the disease do not present with symptoms, enabling the virus to spread within communities. warming global climates are accelerating the presence of mosquito-borne viruses that can cause death to the us, europe and australia there is no specific pharmaceutical treatment and the one vaccine which exists is available to a highly restricted audience. island has repurposed isla-101, an